A. Kulesza

Modeling the disruption of respiratory disease clinical trials by non-pharmaceutical COVID-19 interventions

B. Illigens, J. Boissel, C. Pasquali, 2022, Nature Communications.

Viral kinetic modeling and clinical trial simulation predicts disruption of respiratory disease trials by non-pharmaceutical COVID-19 interventions

A. Chevalier, J. Boissel, B. Illigens, 2021, medRxiv.

Possible Contexts of Use for In Silico Trials Methodologies: A Consensus-Based Review

Simon J. Sonntag, Marco Viceconti, Michael Neidlin, 2021, IEEE Journal of Biomedical and Health Informatics.

Model Integration in Computational Biology: The Role of Reproducibility, Credibility and Utility

Jonathan R. Karr, John P. Rice, Robin N. Thompson, 2022, Frontiers in Systems Biology.

Solving the Evidence Interpretability Crisis in Health Technology Assessment: A Role for Mechanistic Models?

J. Boissel, J. Massol, I. Klingmann, 2022, Frontiers in Medical Technology.

Scientific and regulatory evaluation of mechanistic in silico drug and disease models in drug development: Building model credibility

R. Bursi, F. Pappalardo, L. Geris, 2021, CPT: pharmacometrics & systems pharmacology.

A quantitative systems pharmacology workflow towards optimal design and biomarker stratification of atopic dermatitis clinical trials

D. Lefaudeux, B. S.Martis, N. Go, 2023, medRxiv.

Verifying and Validating Quantitative Systems Pharmacology and In Silico Models in Drug Development: Current Needs, Gaps, and Challenges

Liesbet Geris, Jean-Pierre Boissel, Flora T Musuamba, 2020, CPT: pharmacometrics & systems pharmacology.